DOCSLIB.ORG

See the Meds for Vets Catalog

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Quality Guarantee Fast Turnaround Many Items in Stock Affordable Quality Superior Customer Service Meds for Vets values your business and your patients’ health. We look forward to partnering with you to solve Happy Pets • Happy Owners • Happy Vets™ your most difficult medication challenges. Happy Pets. Happy Owners. Happy Vets.™ Visit us at MedsForVets.com & Facebook.com/MedsForVets YOUR COMPLETE SOURCE FOR COMPOUNDED VETERINARY PHARMACEUTICALS • CALL TOLL FREE: 866 MED-4VET (866-633-4838) A portion of all proceeds is donated to animal-related causes. Solving your most difficult medication challenges While many veterinary patients are amena- designed to hide even the most persistent ble to the limited array of commercially medication tastes. Our Triple Meat suspension available dosage forms, many are not. of chicken, pork and ham works equally well for Commercially produced products are often dogs. Chewable treats and flavored feed addi- designed for humans at strengths too high tives afford the benefits of customized flavor- for the majority of veterinary patients. Tablets ing with pre-measured dosing. Flavored oral and capsules are often too large. Fruity flavorings, while well suited to the majority of pastes offer a convenient equine dosage both exotics, are poorly accepted by many dogs at home and at the track. These and other dos- and cats. Owners often have difficulties age forms can be designed to meet specialized administering even the simplest of dosage needs such as sodium restrictions, sugar-free forms. Add to this the unwillingness of some preparations and others upon request. patients to tolerate any medication knowingly, and even the most effective Transdermal Gels medication may become a clinical failure The most difficult of patients rather quickly. sometimes need to be medicated without even knowing it! Customized Capsules A mixture of both fat-soluble and water-soluble At Meds for Vets, we are able to compounds, Transdermal Gels are suitable provide the dosage form best for almost any medication. All but very large suited to your patient at exactly molecules, e.g. insulin, can be effectively the right dosage. administered through this dosage form. Many patients can be dosed effectively with Because transdermal gels can also be capsules. Because we compound for the absorbed through the skin of the owner, we veterinary field exclusively, we use the provide specialized instructions as well as smallest capsule size possible for each dose. finger cots for both safe and effective admin- While most pharmacies compound primarily istration of these products. with size 1 capsules, too large for all but the largest dog, we compound primarily with size Sterile Injectables and Ophthalmics 3 and 4 capsules, suitable for even the When a sterile product is smallest dogs, cats, and kittens. required, look to Meds for Vets Flavored Suspensions, Chewable Treats, for quality injectables and Feed Additives and Oral Pastes ophthalmics. YOUR COMPLETE SOURCE FOR COMPOUNDED VETERINARY PHARMACEUTICALS • CALL TOLL FREE: 866 MED-4VET Even small capsules may be too Whether you’re looking for sterile eye drops or ointments, small animal or equine difficult to dose for some patients. A portion of all proceeds is donated to animal-related causes. injectables, you will be pleased with the Specialized flavorings are often selection and quality we are able to offer. the answer. Our products are rigorously tested for Our Triple Fish suspension for cats begins potency and sterility from both bacteria and with a puree of salmon, sardines and tuna fungi to ensure your complete satisfaction. Happy Pets. Happy Owners. Happy Vets.™ Visit us at MedsForVets.com & Facebook.com/MedsForVets It all adds up to convenience… Happy pets. Happy owners. Introducing even more dosing choices Happy vets.™ Count on us to simplify your life! Looking for even more dosing choices? Simplify your life with our Simpli-Choices™ to ensure that you’ll find just the right dosage form for you. Simpli-Chew™ Chewable Tablets Simpli-Clear EKT™ Ear Gel Looking for economical, tasty chewable Want a single dose that treats long- tablets? standing ear infections for only pennies Our Simpli-Chew™ meat-flavored chewable per ear? tablets are quarter-scored for the ultimate in A powerful combination of an antibiotic, dosing flexibility. Count on Simpli-Chew™ tablets antifungal and steroid, Simpli-Clear™ EKT has to weigh in as a hit for all of your patients, from been proven effective against even challenging two pounds to two hundred! pseudomonas infections. It’s safe, effective, and best of all, usually only takes one treatment Simpli-Small™ Tablets administered by YOU (no client dosing required!). Looking for an even smaller option? At only 1/4 of an inch in diameter, it’s “Now you Simpli-New™ see it, now you don’t” with our Simpli-Small™ Want to be sure that you will be able to tablets. Smaller than a breath mint, they are easy use your compounded product before the to conceal and can even be placed at the back of expiration date? the tongue, avoiding the taste buds all together! Rest assured with our Simpli-New™ product For an easy to give, affordable option, count on guarantee. Just return any unopened package to Simpli-Small™ tablets. us and we will ship you out a fresh replacement at no cost. It’s just that easy. A portion of all proceeds is donated to animal-related causes. Happy Pets. Happy Owners. Happy Vets.™ Visit us at MedsForVets.com & Facebook.com/MedsForVets (866) MED-4VET BIG or small, no problem at all! When it comes to treating veterinary patients, it can be a real ZOO! But we’ve got you covered with a broad range of creative dosing solutions for any size patient, anywhere. Treating LARGE animals? Try our flavored powders, oral pastes or even flavored medicated crispy rice treats. Clever ones like primates? Try our medicated grape jellies on their favorite cracker. From medicated water sources to specialty treats and other dosage forms, think of Meds for Vets Pharmacy for all of your compounding needs. After all, it can be a real jungle out there! A portion of all proceeds is donated to animal-related causes. Happy Pets. Happy Owners. Happy Vets.™ Visit us at MedsForVets.com & Facebook.com/MedsForVets (866) MED-4VET Representative product list Following are some of the many products that we are able to customize to meet your dosage and flavoring needs. Don’t see a particular product? Call us! We’ll find it for you. A Acepromazine Maleate Amitriptyline HCL Azithromycin capsules, Calcium Glubionate Chlorpheniramine Cyclosporine capsules, capsules, chew treats, capsules, chew treats, chew treats, eye drops, suspension Maletate capsules, chew treats, eye injection, paste, injection, Simpli-Small™, paste, Simpli-Chew™, chew treats, injection, drops, eye ointment, powder, Simpli-Chew™, suspension, transdermal suspension, transdermal Calcium Gluconate suspension, transdermal suspension, topical suspension, transdermal capsules, injection ointment Amlodipine capsules, B Chlorpromazine HCL Acetazolamide capsules, chew treats, Simpli- Bacitracin/Neomycin/ Calcium Levulinate injection, suspension Cyclosporine/Tacrolimus powder, suspension Small™, suspension, Nystatin/Triamcinolone injection eye drops, eye ointment transdermal topical cream, topical Chromium Picolinate Acetyl-Cysteine ointment Calcium powder, suspension Cyproheptadine HCL capsules, eye drops, Ammonium Chloride Glycerophosphate/ capsules, powder, injection, suspension capsules, powder, Benazepril HCL capsules, Calcium Lactate Cidofovir eye drops, eye suspension, transdermal suspension chew treats, suspension, injection ointment Acetyl-D Glucosamine transdermal D injection Amoxicillin capsules, Cantharidin Lactate/ Cimetidine capsules, Danazol capsules chew treats, powder, Betamethasone Acetate/ Salicylic Acid/ injection, paste, powder, ACTH gel, solution suspension, transdermal Betamethasone Sodium Podophyllin topical suspension, transdermal Demecarium Bromide injection Phosphate injection solution eye drops Amoxicillin Sodium Ciprofloxacin HCL Acyclovir eye ointment, injection, inj kit, powder Betamethasone Carbachol injection capsules, chew Desmopressin Acetate suspension, topical Dipropionate/ treats, paste, powder, capsules, eye drops, ointment Amoxicillin/Clavulanate Betamethasone Sodium Cabazochrome suspension, transdermal injection, nasal drop capsules, chew treats, Phosphate injection Salicylate injection Albuterol capsules, powder, Simpli-Chew™, Cisapride Monohydrate Dexamethasone suspension, transdermal suspension, transdermal Bethanechol Chloride Carbimazole capsules capsules, chew treats, capsules, paste, powder, capsules, injection, injection, Simpli- suspension, transdermal Allopurinol capsules, Amphotericin B paste, powder, Carprofen capsules, Chew™, Simpli-Small™, suspension capsules, suspension suspension, transdermal chew treats, Simpli- suspension, transdermal Dexamethasone Chew™, suspension, Sodium Phosphate eye Altrenogest capsules, Ampicillin capsules Bismuth Subcarbonate transdermal Citalopram capsules ointment, injection, paste, suspension capsules, suspension topical cream Ampicillin Sodium Cefadroxil capsules, Clarithromycin capsules, Aluminum Chloride suspension Budesonide capsules, chew treats, suspension suspension Dexpanthenol injection powder chew treats, Simpli- Apomorphine HCL Small™, suspension, Cefpodoxime Proxetil Clindamycin HCL DHEA capsules Aluminum Hydroxide capsules, injection, transdermal suspension capsules, chew treats, capsules, chew treats, tablet triturates
Recommended publications
  • California Proposition 65 Toxicity List

    California Proposition 65 Toxicity List

    STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986 CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY 4-Mar-05 The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and Chemical Type of Toxicity CAS No. Date Listed A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole) cancer 26148685 1-Jan-90 Acetaldehyde cancer 75070 1-Apr-88 Acetamide cancer 60355 1-Jan-90 Acetazolamide developmental 59665 20-Aug-99 Acetochlor cancer 34256821 1-Jan-89 Acetohydroxamic acid developmental 546883 1-Apr-90 2-Acetylaminofluorene cancer 53963 1-Jul-87 Acifluorfen cancer 62476599 1-Jan-90 Acrylamide cancer 79061 1-Jan-90 Acrylonitrile cancer 107131 1-Jul-87 Actinomycin D cancer 50760 1-Oct-89 Actinomycin D developmental 50760 1-Oct-92 Adriamycin (Doxorubicin hydrochloride) cancer 23214928 1-Jul-87 AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide cancer 3688537 1-Jul-87 Aflatoxins cancer --- 1-Jan-88 Alachlor cancer 15972608 1-Jan-89 Alcoholic beverages, when associated with alcohol abuse cancer --- 1-Jul-88 Aldrin cancer 309002 1-Jul-88 All-trans retinoic acid developmental 302794 1-Jan-89 Allyl chloride Delisted October 29, 1999 cancer 107051 1-Jan-90 Alprazolam developmental 28981977 1-Jul-90 Altretamine developmental, male 645056 20-Aug-99 Amantadine hydrochloride developmental 665667 27-Feb-01 Amikacin sulfate developmental 39831555 1-Jul-90 2-Aminoanthraquinone cancer 117793 1-Oct-89 p -Aminoazobenzene cancer
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • COMBINED LIST of Particularly Hazardous Substances

    COMBINED LIST of Particularly Hazardous Substances

    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
  • WSAVA List of Essential Medicines for Cats and Dogs

    WSAVA List of Essential Medicines for Cats and Dogs

    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
  • Management of Cutaneous Hemangiomas in Pediatric Patients

    Management of Cutaneous Hemangiomas in Pediatric Patients

    PEDIATRIC DERMATOLOGY Series Editor: Camila K. Janniger, MD Management of Cutaneous Hemangiomas in Pediatric Patients Maria Letizia Musumeci, MD, PhD; Karina Schlecht, MD, PhD; Rosario Perrotta, MD; Robert A. Schwartz, MD, MPH; Giuseppe Micali, MD Cutaneous hemangiomas (CHs) are common benign during the first year of life and slow involution that vascular tumors of childhood. Clinically, they are usually is completed by 5 to 10 years of age.1 For characterized by a typical evolution profile, consist- this reason, no treatment is necessary in most cases. ing of a rapid proliferation during the first year of However, when CHs are located in areas at risk for life and slow involution that usually is completed functional complications; are of considerable size; or by 5 to 10 years of age. In most cases, no treat- repeatedly undergo bleeding, ulceration, or superin- ment is necessary. However, when CHs are located fection, a prompt and adequate treatment approach in areas at risk for functional complications; are of is required.2 considerable size; or repeatedly undergo bleeding, ulceration, or superinfection, a prompt and adequate Epidemiology treatment approach is required. First-line approaches CHs are present in 1.0% to 2.6% of neonates and in include topical, intralesional, and systemic corti- 10% to 12% of infants by 12 months of age.3 Thirty costeroids. Second-line options include interferon percent of CHs are first evident at birth; the remain- alfa-2a and -2b, laser therapy, and surgical therapy. der appear during the second month of life. The Third-line approaches include cytotoxins, emboliza- frequency of these benign tumors increases in pre- tion, and angiogenesis inhibitors.
  • Pruritus: Scratching the Surface

    Pruritus: Scratching the Surface

    Pruritus: Scratching the surface Iris Ale, MD Director Allergy Unit, University Hospital Professor of Dermatology Republic University, Uruguay Member of the ICDRG ITCH • defined as an “unpleasant sensation of the skin leading to the desire to scratch” -- Samuel Hafenreffer (1660) • The definition offered by the German physician Samuel Hafenreffer in 1660 has yet to be improved upon. • However, it turns out that itch is, indeed, inseparable from the desire to scratch. Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39(2 Pt 1):268-9. Pruritus • “Scratching is one of nature’s sweetest gratifications, and the one nearest to hand….” -- Michel de Montaigne (1553) “…..But repentance follows too annoyingly close at its heels.” The Essays of Montaigne Itch has been ranked, by scientific and artistic observers alike, among the most distressing physical sensations one can experience: In Dante’s Inferno, falsifiers were punished by “the burning rage / of fierce itching that nothing could relieve” Pruritus and body defence • Pruritus fulfils an essential part of the innate defence mechanism of the body. • Next to pain, itch may serve as an alarm system to remove possibly damaging or harming substances from the skin. • Itch, and the accompanying scratch reflex, evolved in order to protect us from such dangers as malaria, yellow fever, and dengue, transmitted by mosquitoes, typhus-bearing lice, plague-bearing fleas • However, chronic itch lost this function. Chronic Pruritus • Chronic pruritus is a common and distressing symptom, that is associated with a variety of skin conditions and systemic diseases • It usually has a dramatic impact on the quality of life of the affected individuals Chronic Pruritus • Despite being the major symptom associated with skin disease, our understanding of the pathogenesis of most types of itch is limited, and current therapies are often inadequate.
  • WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT

    WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT (51) International Patent Classification: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, CI2Q 1/32 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PCT/US2018/021 109 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (22) International Filing Date: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 06 March 2018 (06.03.2018) KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English Declarations under Rule 4.17: (26) Publication Langi English — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H)) (30) Priority Data: — as to the applicant's entitlement to claim the priority of the 62/484,141 11 April 2017 ( 11.04.2017) US earlier application (Rule 4.17(Hi)) (71) Applicant: REGENERON PHARMACEUTICALS, Published: INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, — with international search report (Art. 21(3)) New York 10591-6707 (US). — with sequence listing part of description (Rule 5.2(a)) (72) Inventors: STEVIS, Panayiotis; 777 Old Saw Mill Riv er Road, Tarrytown, New York 10591-6707 (US).
  • Hemorrhoids (1 of 8)

    Hemorrhoids (1 of 8)

    Hemorrhoids (1 of 8) 1 Patient presents w/ symptoms of hemorrhoids 2 DIAGNOSIS No ALTERNATIVE Hemorrhoids confi rmed & other DIAGNOSIS causes of rectal bleeding excluded? Yes Internal or external External TREATMENT hemorrhoids? hemorrhoids See page 3 Internal hemorrhoids 3 GRADE HEMORRHOIDS A Dietary modifi cation & supportive measures B Pharmacological therapy Grade I - II Grade III Grade IV Yes Response to C Ablative offi ce procedures therapy? D Surgical hemorrhoidectomy CONTINUE No TREATMENT C Ablative offi ce procedures Yes Response to No D Surgical hemorrhoidectomy ©therapy? MIMS B1 © MIMS 2019 Hemorrhoids (2 of 8) 1 SYMPTOMS ATTRIBUTED TO HEMORRHOIDS • Rectal bleeding - Most common presenting symptom - Bright red blood which may drip or squirt into the toilet bowl or scanty amounts may be seen on toilet tissue • Discomfort due to rectal protrusion or lump • Anal pain • HEMORRHOIDS Anal itching 2 DIAGNOSIS Medical History • Assess nature, duration & severity of symptoms - Ask about bleeding, its amount & frequency - Ask about presence of prolapsing tissue, its timing & reproducibility • Elicit possible risk factors for development of hemorrhoidal symptoms - Low-fi ber diets cause small-caliber stools, resulting in straining during defecation & engorgement of hemorrhoids - Prolonged sitting on a toilet which may cause a problem in the venous return in the perianal area - Pregnancy - Advanced age • Th e signs & symptoms of hemorrhoids are not specifi c to the disease, so care must be taken to avoid missing other causes of pathology • Obtain
  • Download Our Summer 2010 Newsletter

    Download Our Summer 2010 Newsletter

    A n e w s l e t t e r f o r r e f e r r i n g veterinarians JOIN US IN 2011 AS WE CELEBRATE METROPOLITAN VETERINARY ASSOCIATES 25 P roviding emergency care & specialized veterinary services YEARS INSID E: p2-3 WELCOME TO Trilostane for the Treatment of Canine the fourth edition of our newsletter Hyperadrenocorticism – The Answer to Our Problems? Established in 1986, Metropolitan Veterinary Associates & Emergency Services p4 is a veterinary group that provides referral veterinary services. We concentrate Pet Loss Support Group & Monthly Lecture Series on specialty and emergency cases, allowing us to dedicate high-level care to the following disciplines: behavior, cardiology, dentistry, dermatology, I NSERT: emergency, internal medicine, neurology, ophthalmology, radiology front (including CT and MRI) and surgery. Meet our internal medicine team In order to maintain a high level of patient care, MVA moved into a newly back renovated 18,000 square foot facility with state-of-the-art diagnostic and Join us for CE therapeutic equipment in 2006. If you haven’t been able to visit our practice, we hope you can join us at one of the upcoming hospital lectures mentioned on page 4. Please enjoy this newsletter and let us know of any topics of interest you’d like to see explored in future editions. We’ve made it easier to contact us. Catch us 24 HOURS A DAY at 610/666/1050! (our primary phone number) DID YOU KNOW? TRILOSTANE FOR THE TREATMENT OF ! CANINE HYPERADRENOCORTICISM – THE ANSWER TO OUR PROBLEMS? By: Damon B.
  • Chemical Muscle Enhancement (The BDR) by Author L

    Chemical Muscle Enhancement (The BDR) by Author L

    Chemical Muscle Enhancement (The BDR) By Author L. Rea TABLE OF CONTENTS 1. AAS INTRODUCTION ..PG’S 1-12 WARNING: READ FIRST OVER 20 YEARS AGO... WHY STEROIDS AND WHAT IS POSSIBLE? WHAT ARE STEROIDS? FEMALE HORMONE SYNTHESIS MALE HORMONE SYNTHESIS TESTOSTERONE... WHAT DOES IT DO? STEROIDS INCREASE PC SYNTHESIS STEROIDS EFFECT BLOOD VOLUME WHAT HAPPENS AFTER TESTOSTERONE MOLECULES LEAVE RECEPTORS? STEROIDS...GROWTH ON THE CELULAR LEVEL 2. DRUG REFERENCES AND DESCRIPTIONS..PG 12 ORAL ANABOLIC / ANDROGENIC STEROIDS..PG’S 13-30 INJECTABLE ANABOLIC / ANDROGENIC STEROIDS..PG’S 31-45 TESTOSTERONE AND ITS ESTERS..PG’S 45-61 NORTESTOSTERONE (NANDROLONE) AND ITS ESTER..PG’S 62-70 TRENBOLONE AND DERIVATIVES..PG’S 71-78 ESTROGEN CONTROL AND HPTA REGENERATION DRUGS..PG’S 79-94 DIURETICS..PG’S 95-102 THYROID HORMONES ..PG’S 103-116 NON-AAS GROWTH FACTORS AND RELATED SUBSTANCES..PG’S 117-141 OTHER SUBSTANCES..PG’S 142-152 3. REPORTED CYCLES AND EFFECTS.. (Introduction) PG’S 153-159 REPORTED CYCLES AND EFFECTS EXAMPLES (MALE)...PG’S 160-169 REPORTED CYCLES AND EFFECTS EXAMPLES (FEMALE)...PG’S 170-174 REPORTED ADVANCED CYCLES AND EFFECTS-BLITZ CYCLES..PG’S 175-200 (More Reported Cycles and Effects) 4. NUTRITION..PG’S..201-211 5. SUPPLEMENTAL CREATINE..PG’S 212-216 6. REFERENCES AND AVAILABLE LITERATURE..PG’S 217-223 All Rights Reserved CHEMICAL MUSCLE ENHANCEMENT (The Report) and BODYBUILDERS DESK REFERENCE COPYRIGHT ©2002 by AUTHOR L. REA No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical including photocopy, recording, or by any information storage and retrieval system, without the permission in writing of the author and publisher.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Diagnosis and Treatment of Varicose Veins in the Legs

    Diagnosis and Treatment of Varicose Veins in the Legs

    Diagnosis and treatment of varicose veins in the legs KCE reports 164C Belgian Health Care Knowledge Centre Federaal Kenniscentrum voor de Gezondheidszorg Centre fédéral d’expertise des soins de santé 2011 The Belgian Health Care Knowledge Centre Introduction: The Belgian Health Care Knowledge Centre (KCE) is an organization of public interest, created on the 24th of December 2002 under the supervision of the Minister of Public Health and Social Affairs. KCE is in charge of conducting studies that support the political decision making on health care and health insurance. Executive Board Actual Members: Pierre Gillet (President), Dirk Cuypers (Vice-president), Jo De Cock (Vice-president), Frank Van Massenhove (Vice-president), Maggie De Block, Jean-Pierre Baeyens, Ri de Ridder, Olivier De Stexhe, Johan Pauwels, Daniel Devos, Jean-Noël Godin, Xavier De Cuyper, Paul Palstermans, Xavier Brenez, Rita Thys, Marc Moens, Marco Schetgen, Patrick Verertbruggen, Michel Foulon, Myriam Hubinon, Michael Callens, Bernard Lange, Jean-Claude Praet. Substitute Members: Rita Cuypers, Christiaan De Coster, Benoît Collin, Lambert Stamatakis, Karel Vermeyen, Katrien Kesteloot, Bart Ooghe, Frederic Lernoux, Leo Neels, Greet Musch, Geert Messiaen, Anne Remacle, Roland Lemeye, Annick Poncé, Pierre Smiets, Jan Bertels, Celien Van Moerkerke, Yolande Husden, Ludo Meyers, Olivier Thonon, François Perl. Government commissioner: Yves Roger Management Chief Executive Officer: Raf Mertens Assistant Chief Executive Officer: Jean-Pierre Closon Information Federaal Kenniscentrum